Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

Organon & Co. (NYSE:OGN) Q4 2025 Earnings Call Transcript February 12, 2026 Organon & Co. misses on earnings expectations.

Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire ...

HIV product sales were up 6% in 2025, driven by 7% growth in Biktarvy and a 47% surge in its prevention portfolio. This ...

Sanofi shares fell after the company said Belen Garijo, the chief executive of Germany’s Merck KGaA, would succeed Paul ...

For the year, the portfolio participated strongly, returning 14.28% (investor share), but trailed the index’s 15.91% return.

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...